Harnessing Clinical Insights from Tumor Models Boston 2017

Tumor Models Boston 2017 The 5th Annual Tumour Models Boston event aimed to showcase the latest advancements in the application of preclinical models to enhance the translation of cancer therapies from animal to patient! It was clear two of the showcases really stood out for ...

Repositive and AstraZeneca Announce Initial Members of PDX Consortium

Members Include Boehringer Ingelheim, Merck Group and Horizon Discovery Cambridge, 7 December 2016 ... Repositive, a software company developing novel tools to improve discovery and access to human genomic research data, and AstraZeneca have announced the inaugural members of the PDX Consortium, which was set up ...

Find the right PDX model for your research

There is a desperate need to improve the success of drug development in the field of oncology. The rate at which preclinical agents fail to demonstrate sufficient safety or efficiency in oncology clinical trials has been pegged between 85% to 95% . Furthermore, assuming a drug ...